Research Interests
We are using functional genomic approaches to investigate the nutrient signaling and stress adaptations of cancer cells when exposed to various nutrient deprivations and microenvironmental stress conditions. Recently, we focus on two areas. First, we are elucidating the genetic determinants and disease relevance of ferroptosis, a newly recognized form of cell death. Second, we have identified the mammalian stringent response pathway which is highly similar to bacterial stringent response, but with some very interesting twists and novel mechanisms.
A. The genetic determinants and disease relevance of ferroptosis
Ferroptosis is a newly recognized form of cell death that is characterized by iron dependency and lipid peroxidation. The importance of ferroptosis is being recognized in many human diseases, including cancers, ischemia injuries, and neurodegeneration. Previously, we have identified the profound cystine addiction of renal cell carcinoma (1), breast cancer cells (2, 3), and ovarian cancer cells (4). Based on the concept that cystine deprivation triggers the ferroptosis due to the unopposed oxidative stresses, we have performed functional genomic screens to identify many novel genetic determinants of ferroptosis. For example, we have found that DNA damage response and ATM kinase regulate ferroptosis via affecting iron metabolism (5). This finding supports the potential of ionizing radiation to trigger DNA damage response and synergize with ferroptosis to treat human cancers. In addition, we found that ferroptosis is highly regulated by cell density. When cells are grown at low density, they are highly susceptible to ferroptosis. In contrast, the same cells become resistant to ferroptosis when grown at high density and confluency. we have found the Hippo pathway effectors TAZ and YAP are responsible for the cell density-dependent ferroptosis (4, 6, 7). Right now, we are pursuing several other novel determinants of ferroptosis that will reveal surprising insights into this new form of cell death.
B. A new stress pathway – mammalian stress response
All living organisms encounter a wide variety of nutrient deprivations and environmental stresses. Therefore, all organisms have developed various mechanisms to respond and promote survival under stress. In bacteria, the main strategy is “stringent response” triggered by the accumulation of the alarmone (p)ppGpp (shortened to ppGpp below) via regulation of its synthetase RelA and its hydrolase SpoT (8). The ppGpp binds to the transcription factor DksA and RNA polymerase to orchestrate extensive transcriptional changes that repress proliferation and promote stress survival (8, 9). While highly conserved among bacteria, the stringent response had not been reported in metazoans. However, a recent study identified Drosophila and human MESH1 (Metazoan SpoT Homolog 1) as the homologs of the ppGpp hydrolase domain of the bacterial SpoT (10). Both MESH1 proteins exhibit ppGpp hydrolase activity, and the deletion of Mesh1 in Drosophila led to a transcriptional response reminiscent of the bacterial stringent response (10). Recently, we have found that the genetic removal of MESH1 in tumor cells triggers extensive transcriptional changes and confers protection against oxidative stress-induced ferroptosis (11). Importantly, MESH1 removal also triggers proliferative arrest and other robust anti-tumor effects. Therefore, MESH1 knockdown leads to both stress survival and proliferation arrest, two cardinal features highly reminiscent of the bacterial stringent response. Therefore, we termed this pathway as “mammalian stringent response” (12). We have found that NADPH is the relevant MESH1 in the contexts of ferroptosis (13). Now, we are investigating how MESH1 removal leads to proliferation of arrests and anti-tumor phenotypes. Furthermore, we have found several other substrates of MESH1. We are investigating their function using culture cells, MESH1 KO mice, and other model organisms.
C. Genomic and single cell RNA analysis of Red Blood Cells
Red blood cells (RBC) are responsible for oxygen delivery to muscles during vigorous exercise. Therefore, many doping efforts focus on increasing RBC number and function to boost athletic performance during competition. For many decades, RBC were thought to be merely identical “sacs of hemoglobin” with no discernable differences due to factors such as age or pre-transfusion storage time. Additionally, because RBC lose their nuclei during terminal differentiation, they were not believed to retain any genetic materials. These long-held beliefs have now been disproven and the results have significant implications for detecting autologous blood transfusion (ABT) doping in athletes. We were among the first to discover that RBCs contain abundant and diverse species of RNAs. Using this knowledge, we subsequently optimized protocols and performed genomic analysis of the RBC transcriptome in sickle cell disease; these results revealed that heterogeneous RBCs could be divided into several subpopulations, which had implications for the mechanisms of malaria resistance. As an extension of these studies, we used high resolution Illumina RNA-Seq approaches to identify hundreds of additional known and novel microRNAs, mRNAs, and other RNA species in RBCs. This dynamic RBC transcriptome represents a significant opportunity to assess the impact that environmental factors (such as pre-transfusion refrigerate storage) on the RBC transcriptome. We have now identified a >10-fold change in miR-720 as well as several other RNA transcripts whose levels are significantly altered by RBC storage (14) which gained significant press coverage. We are pursuing the genomic and single cell analysis of RNA transcriptome in the context of blood doping, sickle cell diseases and other red cell diseases.
1. Tang X, Wu J, Ding CK, Lu M, Keenan MM, Lin CC, et al. Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas. Cancer Res. 2016;76(7):1892-903.
2. Tang X, Ding CK, Wu J, Sjol J, Wardell S, Spasojevic I, et al. Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. Oncogene. 2017;36(30):4379.
3. Lin CC, Mabe NW, Lin YT, Yang WH, Tang X, Hong L, et al. RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence. Cell Death Differ. 2020.
4. Yang WH, Huang Z, Wu J, Ding C-KC, Murphy SK, Chi J-T. A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer. Molecular Cancer Research. 2019: molcanres.0691.2019.
5. Chen PH, Wu J, Ding CC, Lin CC, Pan S, Bossa N, et al. Kinome screen of ferroptosis reveals a novel role of ATM in regulating iron metabolism. Cell Death Differ. 2019.
6. Yang W-H, Chi J-T. Hippo pathway effectors YAP/TAZ as novel determinants of ferroptosis. Molecular & Cellular Oncology. 2019:1699375.
7. Yang WH, Ding CKC, Sun T, Hsu DS, Chi JT. The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma Cell Reports. 2019;28(10):2501-8.e4.
8. Potrykus K, Cashel M. (p)ppGpp: still magical? Annu Rev Microbiol. 2008;62:35-51.
9. Kriel A, Bittner AN, Kim SH, Liu K, Tehranchi AK, Zou WY, et al. Direct regulation of GTP homeostasis by (p)ppGpp: a critical component of viability and stress resistance. Mol Cell. 2012;48(2):231-41.
10. Sun D, Lee G, Lee JH, Kim HY, Rhee HW, Park SY, et al. A metazoan ortholog of SpoT hydrolyzes ppGpp and functions in starvation responses. Nat Struct Mol Biol. 2010;17(10):1188-94.
11. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-72.
12. Ding C-KC, Rose J, Wu J, Sun T, Chen K-Y, Chen P-H, et al. Mammalian stringent-like response mediated by the cytosolic NADPH phosphatase MESH1. bioRxiv. 2018.
13. Ding C-KC, Rose J, Sun T, Wu J, Chen P-H, Lin C-C, et al. MESH1 is a cytosolic NADPH phosphatase that regulates ferroptosis. Nature Metabolism. 2020.
14. Yang WH, Doss JF, Walzer KA, McNulty SM, Wu J, Roback JD, et al. Angiogenin-mediated tRNA cleavage as a novel feature of stored red blood cells. Br J Haematol. 2018.
Selected Grants
2/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Institutes of Health · 2025 - 2030Thioredoxin derivatives for radiation mitigation
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2030Targeting Hepatocyte Senescence to Improve NAFLD
ResearchCo-Mentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029The Duke Preparing Research scholars In bioMEdical sciences (PRIME): Cancer Research Program
ResearchPreceptor · Awarded by National Cancer Institute · 2023 - 2028Duke KURe Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2013 - 2028A randomized controlled phase 2 study of the ketogenic diet for patients with newly diagnosed glioblastoma in combination with standard-of-care treatment
ResearchCo Investigator · Awarded by Cedars Sinai Medical Center · 2023 - 2028Targeting Stiffness-Enhanced Ferroptosis to Overcome Chemoresistance in UPS
ResearchPrincipal Investigator · Awarded by The Paula Takacs Foundation For Sarcoma Research · 2026 - 2027The Role of Kidney Macrophage MESH1 in Chronic Kidney Diseases
FellowshipSignificant Contributor · Awarded by American Heart Association · 2026 - 2027Noncovalent interaction of mutant KRAS inhibitors
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2025 - 2027Medical Scientist Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of General Medical Sciences · 2022 - 2027Duke ACS Institutional Research Grant
ResearchSignificant Contributor · Awarded by American Cancer Society, Inc. · 2024 - 2026Targeting Environmental Ferroptosis Protection as Novel Therapeutic Strategy for Metastatic Renal Cell Carcinoma
ResearchPrincipal Investigator · Awarded by Department of Defense · 2023 - 2026Cell and Molecular Biology Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of General Medical Sciences · 2021 - 2026Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 1975 - 2026Non-canonical role of Ninjurin 1 (NINJ1) in the ferroptosis of recurrent ovarian cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2024 - 2026The role of ferroptosis in the metastatic ovarian cancer
ResearchPrincipal Investigator · Awarded by Ovarian Cancer Research Alliance · 2022 - 2025Genetic and Genomics Training Grant
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2020 - 2025Disabling metastasis by the targeting the ferroptosis protection mechanism of serum
ResearchPrincipal Investigator · Awarded by Department of Defense · 2023 - 2025A consortium effort to translate therapies for neurological diseases via an immune-competent organotypic platform
ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2021 - 2025Summer Scholars in Genome Sciences & Medicine
Inst. Training Prgm or CMESignificant Contributor · Awarded by National Institutes of Health · 2017 - 2025Development of MESH1 inhibitors to treat ferroptosis-associated neurodegeneration
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2022 - 2024Duke CTSA (TL1) Year 5
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024Hippo-Yap Pathway, Ferroptosis of Hepatic Stellate Cells and Liver Fibrosis
ResearchCo-Mentor · Awarded by American Association for the Study of Liver Diseases · 2021 - 2024Biochemical and functional investigation of the novel enzymatic activities of Mesh1
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2024Metabolic regulation of KLHL proteins through glycosylation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2024Enhancing immunotherapy by triggering ferroptosis
ResearchPrincipal Investigator · Awarded by Department of Defense · 2021 - 2024Therapeutic targeting of MESH1 in renal cell carcinoma
ResearchPrincipal Investigator · Awarded by Department of Defense · 2020 - 2023Postdoctoral Training in Genomic Medicine Research
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2017 - 2023Single cell RNA-Seq of stored RBC to detect Autologous Blood Transfusion
ResearchPrincipal Investigator · Awarded by Partnership for Clean Competition · 2021 - 2023The regulation dephosphorylated-CoA-capped RNA and innate immunity by MESH1
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2023Therapeutic targeting of cystine addiction of renal cell carcinoma
ResearchPrincipal Investigator · Awarded by Department of Defense · 2019 - 2022Medical Scientist Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1997 - 2022Characterization of NYP Peptides in Prostate Cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2021Bioinformatics and Computational Biology Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2005 - 2021Validation of the in vitro storage signature in an independent cohort of human doping trial
ResearchPrincipal Investigator · Awarded by Partnership for Clean Competition · 2020 - 2020Targeting the Hippo pathway in Ras-driven rhabdomyosarcoma
ResearchCollaborator · Awarded by V Foundation for Cancer Research · 2016 - 2020Genetics Training Grant
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1979 - 2020Organization and Function of Cellular Structure
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1975 - 2020Storage-specific erythrocyte gene signatures to detect autologous transfusion
ResearchPrincipal Investigator · Awarded by Partnership for Clean Competition · 2017 - 2019Investigating the role of the transcriptional coactivator TAZ in alveolar rhabdomyosarcoma
ResearchCollaborator · Awarded by St. Baldrick's Foundation · 2016 - 2019Detect autologous transfusion by novel separation and characterization of RBC storage exosomes
ResearchPrincipal Investigator · Awarded by Partnership for Clean Competition · 2018 - 2019Thermo Lumos Tribrid High-Resolution Accurate-Mass Tandem Mass Spectrometer
EquipmentMajor User · Awarded by National Institutes of Health · 2018 - 2019Duke-UNC Clinical Hematology and Transfusion Research Career Development Program
ResearchMentor · Awarded by National Institutes of Health · 2006 - 2019Development of Prognostic Platelet RNA Biomarkers To Tailor Antiplatelet Therapy
ResearchCo Investigator · Awarded by National Institutes of Health · 2013 - 2019Triggering human anti-tumor stringent response to target recurrent ovarian cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2017 - 2019Human Stringent Response as Novel Therapeutic Approaches for Breast Cancers
ResearchPrincipal Investigator · Awarded by Department of Defense · 2015 - 2018Immune regulated amino acid pathways in Alzheimer's Disease
ResearchCollaborating Investigator · Awarded by National Institutes of Health · 2016 - 2018Gene expression programs of lactic acidosis in human cancers
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2007 - 2018Targeting the synthetic essential kinases of breast cancers
ResearchPrincipal Investigator · Awarded by Department of Defense · 2015 - 2018Small RNA transcriptome as novel approaches to detect autologous blood transfusion
ResearchPrincipal Investigator · Awarded by World Anti-Doping Agency · 2016 - 2018Comparison of oxidant damage, Nrf2 characteristics, and gene modification of cord blood versus plerixafor-mobilized adult CD34+ cells from sickle cell disease patients
ResearchPrincipal Investigator · Awarded by New York Blood Center · 2016 - 2017Functional Genomic Screens of Tumor Recurrence in Ovarian Cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2014 - 2017Cancer Biology Training Grant
Inst. Training Prgm or CMEMentor · Awarded by National Cancer Institute · 1993 - 2016Oncogenic Gene Regulatory Networks
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2004 - 2015Genetic elements of cancer cell survival in tumor microenvironment stresses
FellowshipPrincipal Investigator · Awarded by National Institutes of Health · 2013 - 2015Detecting autologous blood doping through the analysis of erythrocyte transcriptome
ResearchPrincipal Investigator · Awarded by World Anti-Doping Agency · 2014 - 2015Instrumentation for Quantitative Phosphoproteomics and Acetylomics
EquipmentMajor User · Awarded by National Institutes of Health · 2014 - 2015InCh Microscope: Compact and Portable Quantitative Phase Microscope for Label-Free Morphological Diagnosis of Blood Samp
ResearchCo Investigator · Awarded by M2 Photonics Innovations · 2014 - 2014Resveratrol, Carbohydrate Restriction and Prostate Cancer Progression
ResearchInvestigator · Awarded by National Institutes of Health · 2008 - 2014Molecular Modeling of Pediatric Skeletal Muscle Tumors
ResearchCollaborator · Awarded by National Institutes of Health · 2009 - 2013Illumina Hi-Seq 2000 Sequencing System
EquipmentMajor User · Awarded by National Institutes of Health · 2012 - 2013Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2009 - 2012The Genomic Analysis of Erythrocyte microRNA in Sickle Cell Diseases
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2008 - 2011External Relationships
- Guidepoint Global
- National Health Research Institute, Taiwan
- National Tsing Hua University, Taiwan
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.